|
176 Companies |
|
232 Products |
|
232 Products |
|
108 Mechanisms of Action |
|
9 Trials |
|
1978 News |
|
| «12...89101112131415161718...4142» |
- |||| Rydapt (midostaurin) / Novartis
Trial completion, Trial primary completion date: PKC412 and 5-Azacytidine (clinicaltrials.gov) - Jul 21, 2015
P1/2, N=57, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jul 2015
- cytarabine / Generic mfg., clofarabine / Generic mfg., sorafenib / Generic mfg.
Trial completion, Enrollment change, Combination therapy: Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies (clinicaltrials.gov) - Jul 13, 2015
P1, N=44, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jul 2015 Recruiting --> Completed | N=60 --> 44
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial initiation date, Combination therapy, Metastases: Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes (clinicaltrials.gov) - Jul 10, 2015
P2, N=30, Completed, Sponsor: The Cleveland Clinic
Recruiting --> Completed | N=60 --> 44 Initiation date: Jun 2004 --> Feb 2004
- Xospata (gilteritinib) / Astellas
Enrollment change, Trial primary completion date: Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 10, 2015
P1/2, N=290, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Initiation date: Jun 2004 --> Feb 2004 N=230 --> 290 | Trial primary completion date: Jun 2015 --> Dec 2015
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Enrollment change, Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant (clinicaltrials.gov) - Jul 10, 2015
P2, N=6, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=230 --> 290 | Trial primary completion date: Jun 2015 --> Dec 2015 Active, not recruiting --> Completed | N=88 --> 6 | Trial primary completion date: Sep 2014 --> Dec 2011
- | StemEx (carlecortemcel-L) / Gamida Cell
Trial completion, Trial primary completion date: ExCell: Efficacy and Safety Study of StemEx (clinicaltrials.gov) - Jul 10, 2015
P2/3, N=101, Completed, Sponsor: Gamida Cell -Teva Joint Venture Ltd.
Active, not recruiting --> Completed | N=88 --> 6 | Trial primary completion date: Sep 2014 --> Dec 2011 Active, not recruiting --> Completed | Trial primary completion date: Jul 2013 --> Feb 2013
- NN1213 / Novo Nordisk
Trial primary completion date, Metastases: Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss (clinicaltrials.gov) - Jul 9, 2015
P1/2, N=63, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial primary completion date: Jul 2013 --> Feb 2013 Trial primary completion date: Nov 2004 --> Jul 2004
- | Zolinza (vorinostat) / Merck (MSD)
Enrollment open: S1203: Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 9, 2015
P3, N=784, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2004 --> Jul 2004 Suspended --> Recruiting
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment closed: An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients (clinicaltrials.gov) - Jul 9, 2015
P2, N=24, Active, not recruiting, Sponsor: Celator Pharmaceuticals
Suspended --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2 (clinicaltrials.gov) - Jul 9, 2015
P=N/A, N=451, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting Recruiting --> Completed
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion: Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 9, 2015
P2, N=92, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant (clinicaltrials.gov) - Jul 9, 2015
P2, N=12, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 12 | Trial primary completion date: Dec 2015 --> Jul 2015
- | baclofen / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer (clinicaltrials.gov) - Jul 9, 2015
P3, N=211, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | N=30 --> 12 | Trial primary completion date: Dec 2015 --> Jul 2015 Active, not recruiting --> Completed | N=148 --> 211 | Trial primary completion date: Jan 2010 --> Apr 2009
- balixafortide (POL 6326) / Spexis
Enrollment change, Trial primary completion date, Metastases: Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jul 6, 2015
P1/2, N=80, Recruiting, Sponsor: Polyphor Ltd.
Active, not recruiting --> Completed | N=148 --> 211 | Trial primary completion date: Jan 2010 --> Apr 2009 N=60 --> 80 | Trial primary completion date: Dec 2014 --> Dec 2016
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change, Trial termination, Trial primary completion date: Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - Jul 6, 2015
P1/2, N=50, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
N=60 --> 80 | Trial primary completion date: Dec 2014 --> Dec 2016 N=90 --> 50 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2014 --> Mar 2011
- talacotuzumab (JNJ-56022473) / J&J
Enrollment closed, Trial primary completion date: A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission (clinicaltrials.gov) - Jul 2, 2015
P1, N=36, Active, not recruiting, Sponsor: CSL Limited
N=90 --> 50 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2014 --> Mar 2011 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Dec 2015
- || fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Jun 30, 2015
P1/2, N=225, Recruiting, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: Dec 2016 --> Mar 2015
- Trial primary completion date: Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy (clinicaltrials.gov) - Jun 26, 2015
P=N/A, N=650, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2016 --> Mar 2015 Trial primary completion date: Nov 2016 --> Nov 2017
- |||| ondansetron / Generic mfg., cytarabine / Generic mfg.
Trial completion: Ondansetron Versus Aprepitant Plus Ondansetron for Emesis (clinicaltrials.gov) - Jun 25, 2015
P2, N=100, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2016 --> Nov 2017 Active, not recruiting --> Completed
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment closed: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 24, 2015
P1, N=61, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- cytarabine / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Epigenetic controller: Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine (clinicaltrials.gov) - Jun 24, 2015
P1/2, N=36, Completed, Sponsor: University of Bergen
Recruiting --> Active, not recruiting Recruiting --> Completed | N=25 --> 36 | Trial primary completion date: Dec 2011 --> Feb 2013
- Trial completion, Enrollment change: Differentiation Induction in Acute Myelogenous Leukemia (clinicaltrials.gov) - Jun 24, 2015
P1/2, N=24, Completed, Sponsor: University of Bergen
Recruiting --> Completed | N=25 --> 36 | Trial primary completion date: Dec 2011 --> Feb 2013 Active, not recruiting --> Completed | N=30 --> 24
- ||||||| zosuquidar (LY335979) / Kanisa Pharma
Trial completion: Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia (clinicaltrials.gov) - Jun 24, 2015
P3, N=449, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed | N=30 --> 24 Active, not recruiting --> Completed
- || bupropion / Generic mfg.
Trial primary completion date: Bupropion in Helping Adults Stop Smoking (clinicaltrials.gov) - Jun 23, 2015
P2, N=97, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: May 2009 --> May 2008
- Simulect (basiliximab) / Novartis
Enrollment closed, Trial primary completion date, IO biomarker: Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission (clinicaltrials.gov) - Jun 23, 2015
P1, N=36, Active, not recruiting, Sponsor: University of Chicago
Trial primary completion date: May 2009 --> May 2008 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
- || Trial primary completion date: Acceptability of Less Harmful Alternatives to Cigarettes (clinicaltrials.gov) - Jun 22, 2015
P=N/A, N=67, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Nov 2009 --> Aug 2009
- Trial suspension: Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jun 22, 2015
P=N/A, N=10, Suspended, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Nov 2009 --> Aug 2009 Recruiting --> Suspended
- Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment change, Trial termination, Trial primary completion date: Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 22, 2015
P1/2, N=12, Terminated, Sponsor: University Health Network, Toronto
Recruiting --> Suspended N=46 --> 12 | Recruiting --> Terminated | Trial primary completion date: Mar 2014 --> Apr 2015
- Enrollment change, Trial termination, Trial primary completion date: Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy (clinicaltrials.gov) - Jun 22, 2015
P1, N=11, Terminated, Sponsor: University Health Network, Toronto
N=46 --> 12 | Recruiting --> Terminated | Trial primary completion date: Mar 2014 --> Apr 2015 N=48 --> 11 | Recruiting --> Terminated | Trial primary completion date: Aug 2011 --> Sep 2013
- Trial completion, Enrollment change, Trial primary completion date: Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy (clinicaltrials.gov) - Jun 22, 2015
P1, N=20, Completed, Sponsor: University Health Network, Toronto
N=48 --> 11 | Recruiting --> Terminated | Trial primary completion date: Aug 2011 --> Sep 2013 Active, not recruiting --> Completed | N=30 --> 20 | Trial primary completion date: Oct 2013 --> May 2013
- Trial termination: Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy (clinicaltrials.gov) - Jun 20, 2015
P2, N=4, Terminated, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed | N=30 --> 20 | Trial primary completion date: Oct 2013 --> May 2013 Active, not recruiting --> Terminated; Lack of funding
- | lenalidomide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients (clinicaltrials.gov) - Jun 20, 2015
P2, N=24, Completed, Sponsor: University Health Network, Toronto
Active, not recruiting --> Terminated; Lack of funding Recruiting --> Completed | N=60 --> 24 | Trial primary completion date: Feb 2011 --> Apr 2015
- tirbanibulin oral (KX2-391 oral) / Hanmi, Athenex
Trial primary completion date: Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Jun 16, 2015
P1, N=20, Active, not recruiting, Sponsor: Kinex Pharmaceuticals Inc
Recruiting --> Completed | N=60 --> 24 | Trial primary completion date: Feb 2011 --> Apr 2015 Trial primary completion date: Jun 2013 --> Sep 2015
- tetradecanoylphorbol acetate (PD-616) / Biosuccess Biotech, Rich Pharma
Trial termination, IO biomarker: Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies (clinicaltrials.gov) - Jun 15, 2015
P2, N=1, Terminated, Sponsor: Rutgers, The State University of New Jersey
Trial primary completion date: Jun 2013 --> Sep 2015 Completed --> Terminated; Study was terminated early due to lack of experimental medication (supply issues)
- Enrollment closed, Trial primary completion date: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=15, Active, not recruiting, Sponsor: University of Washington
Completed --> Terminated; Study was terminated early due to lack of experimental medication (supply issues) Trial primary completion date: Apr 2016 --> Apr 2015 | Recruiting --> Active, not recruiting
- || buparlisib (AN2025) / Adlai Nortye
Trial primary completion date: SIGNATURE: BKM120 for Patients With PI3K-activated Tumors (clinicaltrials.gov) - Jun 11, 2015
P2, N=145, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2016 --> Apr 2015 | Recruiting --> Active, not recruiting Trial primary completion date: May 2015 --> May 2016
- || foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Trial primary completion date, Metastases: Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=104, Recruiting, Sponsor: Prism Pharma Co., Ltd.
Trial primary completion date: May 2015 --> May 2016 Trial primary completion date: May 2015 --> Oct 2015
- Trial withdrawal: Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=0, Withdrawn, Sponsor: Rutgers, The State University of New Jersey
Trial primary completion date: May 2015 --> Oct 2015 Terminated --> Withdrawn
- Zolinza (vorinostat) / Merck (MSD)
Trial suspension: S1203: Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 11, 2015
P3, N=784, Suspended, Sponsor: National Cancer Institute (NCI)
Terminated --> Withdrawn Recruiting --> Suspended
- cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial initiation date, Trial primary completion date, Combination therapy: Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 11, 2015
P2, N=195, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Suspended Initiation date: Mar 1994 --> Sep 1994 | Trial primary completion date: Sep 2015 --> Sep 2016
- decitabine / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Jun 6, 2015
P1, N=0, Withdrawn, Sponsor: University of Louisville
Initiation date: Mar 1994 --> Sep 1994 | Trial primary completion date: Sep 2015 --> Sep 2016 N=10 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2016 --> Jun 2015
- ||| carboplatin / Generic mfg., decitabine / Generic mfg.
Enrollment closed: A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jun 4, 2015
P2, N=120, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=10 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2016 --> Jun 2015 Recruiting --> Active, not recruiting
- Elitek (rasburicase) / Sanofi
Enrollment change, Trial termination: Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - May 29, 2015
P2, N=21, Terminated, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting N=36 --> 21 | Recruiting --> Terminated; low accrual
- tetradecanoylphorbol acetate (PD-616) / Biosuccess Biotech, Rich Pharma
Trial completion, Enrollment change, Trial primary completion date, IO biomarker: Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies (clinicaltrials.gov) - May 27, 2015
P2, N=1, Completed, Sponsor: Rutgers, The State University of New Jersey
N=36 --> 21 | Recruiting --> Terminated; low accrual Active, not recruiting --> Completed | N=20 --> 1 | Trial primary completion date: Jan 2015 --> Oct 2011
- |||| Synribo (omacetaxine mepesuccinate) / Teva
Enrollment open, Trial initiation date, Trial primary completion date: Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - May 26, 2015
P2, N=66, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=20 --> 1 | Trial primary completion date: Jan 2015 --> Oct 2011 Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> May 2015 | Trial primary completion date: Aug 2018 --> May 2018
- Enrollment change, Trial primary completion date: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (clinicaltrials.gov) - May 21, 2015
P1, N=13, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> May 2015 | Trial primary completion date: Aug 2018 --> May 2018 N=18 --> 13 | Trial primary completion date: Dec 2014 --> Mar 2015
- ||| Xpovio (selinexor) / Karyopharm
Enrollment open, Combination therapy: Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - May 21, 2015
P1, N=60, Recruiting, Sponsor: Bhavana Bhatnagar
N=18 --> 13 | Trial primary completion date: Dec 2014 --> Mar 2015 Not yet recruiting --> Recruiting
- Enrollment closed, Enrollment change, Trial primary completion date: HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies (clinicaltrials.gov) - May 21, 2015
P2, N=40, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=66 --> 40 | Trial primary completion date: May 2016 --> Mar 2015
- |||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion: Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies (clinicaltrials.gov) - May 21, 2015
P2, N=84, Completed, Sponsor: Seattle Genetics, Inc.
Recruiting --> Active, not recruiting | N=66 --> 40 | Trial primary completion date: May 2016 --> Mar 2015 Active, not recruiting --> Completed
- Enrollment open: Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (clinicaltrials.gov) - May 20, 2015
P1, N=18, Recruiting, Sponsor: Robert Lowsky
Active, not recruiting --> Completed Active, not recruiting --> Recruiting